MPL and essential thrombocythemia: In addition to the JAK2-V617F mutation, activating point mutations in the thrombopoietin receptor MPL (MPL-W515L/K) and a few other MPL exon 10 mutations have been discovered in 4% to 6% of ET and PMF, but not in PV patients [6,7].